Table 9 Ongoing clinical trials of therapeutic anticoagulation in COVID-19
NCT number | Study name | Interventions | Sponsor |
|---|---|---|---|
NCT04377997 | Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19 | Evaluation of therapeutic enoxaparin | Massachusetts General Hospital (USA) |
NCT04394377 | Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial | Evaluation of therapeutic anticoagulation with rivaroxaban 20 mg/day vs prophylactic enoxaparin 40 mg/day | Brazilian Clinical Research Institute (Brazil) |
NCT04359277 | A Randomized Trial of Anticoagulation Strategies in COVID-19 | Evaluation of therapeutic high dose enoxaparin vs standard prophylactic dose | NYU Langone Health (USA) |
NCT04359277 | Evaluation of therapeutic high dose Enoxaparin versus standard prophylactic dose Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) | Evaluation of varying anticoagulation regimens including enoxaparin, UFH, fondaparinux, and argatroban | Weill Medical College of Cornell University (USA) |
NCT04362085 | Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care | Evaluation of therapeutic anticoagulation vs standard of care prophylaxis | St Michael’s Hospital (Canada) |